Marker Therapeutics (MRKR) Stock Forecast & Price Target $1.18 +0.04 (+3.51%) As of 02:04 PM Eastern Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Marker Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Strong BuyBased on 4 Analyst RatingsSell0Hold0Buy4 Based on 4 Wall Street analysts who have issued ratings for Marker Therapeutics in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 4 analysts, 2 have given a buy rating, and 2 have given a strong buy rating for MRKR. Consensus Price Target $13.171,015.82% Upside According to the 4 analysts' twelve-month price targets for Marker Therapeutics, the average price target is $13.17. The highest price target for MRKR is $19.00, while the lowest price target for MRKR is $8.00. The average price target represents a forecasted upside of 1,015.82% from the current price of $1.18. Get the Latest News and Ratings for MRKR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Marker Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up MRKR Analyst Ratings Over TimeTypeCurrent Forecast4/2/24 to 4/2/251 Month Ago3/3/24 to 3/3/253 Months Ago1/3/24 to 1/2/251 Year Ago4/3/23 to 4/2/24Strong Buy2 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s) N/A Buy2 Buy rating(s)1 Buy rating(s)1 Buy rating(s) N/A Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s) N/A Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s) N/A Consensus Price Target$13.17$19.00$19.00N/AForecasted Upside1,015.82% Upside1,210.34% Upside497.48% UpsideN/AConsensus RatingStrong BuyStrong BuyBuyN/A Remove Ads MRKR Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MRKR Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Marker Therapeutics Stock vs. The CompetitionTypeMarker TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 3.50 2.81 2.54Consensus RatingStrong BuyModerate BuyModerate BuyPredicted Upside1,054.97% Upside19,529.46% Upside19.51% UpsideNews Sentiment RatingNeutral NewsSee Recent MRKR NewsPositive NewsPositive News Remove Ads Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails4/1/2025WBB Securities1 of 5 starsSteve BrozakSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.50+916.25%3/5/2025Canaccord Genuity Group1 of 5 starsJohn NewmanSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.00+479.71%2/10/2025Brookline Capital Management2 of 5 starsL. CannSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy10/21/2024LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$11.00 ➝ $19.00+420.55%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:28 PM ET. MRKR Forecast - Frequently Asked Questions What is Marker Therapeutics' forecast for 2025? According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Marker Therapeutics is $13.17, with a high forecast of $19.00 and a low forecast of $8.00. Should I buy or sell Marker Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last year. There are currently 2 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" MRKR shares. Does Marker Therapeutics's stock price have much upside? According to analysts, Marker Therapeutics's stock has a predicted upside of 1,015.82% based on their 12-month stock forecasts. Has Marker Therapeutics been upgraded by Wall Street analysts recently? Over the previous 90 days, Marker Therapeutics's stock had 1 upgrade by analysts. What analysts cover Marker Therapeutics? Marker Therapeutics has been rated by research analysts at Brookline Capital Management, Canaccord Genuity Group, and WBB Securities in the past 90 days. Do Wall Street analysts like Marker Therapeutics more than its competitors? Analysts like Marker Therapeutics more than other "medical" companies. The consensus rating for Marker Therapeutics is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRKR compares to other companies. Stock Forecasts and Research Tools Related Companies CTMX Stock Forecast MGX Stock Forecast GANX Stock Forecast ALGS Stock Forecast ADAP Stock Forecast KRON Stock Forecast ATNM Stock Forecast TNYA Stock Forecast FBRX Stock Forecast SKYE Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:MRKR) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRKR Stock Free MRKR Stock Alerts